Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Serascience Limited, a specialist cancer diagnostics company established by a joint venture between Abingdon Health and the University of Birmingham, announces the receipt of European CE Mark approval for the commercial sale of Seralite®, its proprietary point-of-care diagnostic device for multiple myeloma.
The approval allows the Company to market the world's first point-of-care diagnostic device in multiple myeloma in the 30 countries that comprise the European Union (EU) and the European Free Trade Association (EFTA). Product evaluations are currently being carried out in key clinics across the UK, and discussions are underway with a number of international distributors.
Dr Chris Hand, Chief Executive Officer of Abingdon Health and Serascience, commented: "The European approval of our first point-of-care product is a significant achievement, marking a key point in the continued growth of our company. Multiple myeloma is the second most common type of blood cancer and we believe Seralite® has the potential to help improve outcomes for patients by providing clinicians with an immediate result that will enable them to quickly start or change treatment options. Since the test was launched for research in April, we have seen growing interest from the myeloma community and we look forward to rolling it out across Europe."
Seralite® is an easy to use, point-of-care device that delivers clear, accurate results within ten minutes. It is aimed for use in hospitals and specialist clinics to aid the diagnosis of myeloma and to monitor relapse and MGUS (Monoclonal gammopathies of undetermined significance) progression. The test measures two markers of myeloma, kappa and lambda free light chains, and calculates the ratio of these two parameters in urine or serum.
The current clinical practice involves sending test samples to laboratories for analysis and waiting up to ten days for the results. Seralite® will allow clinicians to quickly respond to results, allowing them to immediately start treatment and potentially assess if a current treatment regime is working. It will also provide economic benefits by reducing the number of outpatient visits and enabling faster tracking of disease progression.
Multiple myeloma is the second most common type of blood cancer1 with 1,000 new cases diagnosed globally every day. The disease has a high rate of deterioration and a poor prognosis. Delays in diagnosis can result in anaemia, infection and severe damage to the kidneys and skeleton. Studies show that when first diagnosed, up to 40% of myeloma patients may already be experiencing renal failure. Rapid diagnosis and early treatment can prevent the development of these severe complications of myeloma and as a result can greatly improve quality and duration of life.
 The International Myeloma Foundation (IMF)
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Medical Devices / Diagnostics category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Serascience. "CE Mark approval for Seralite® announced, the world's first point-of-care diagnostic device for multiple myeloma." Medical News Today. MediLexicon, Intl., 28 Aug. 2013. Web.
8 Dec. 2013. <http://www.medicalnewstoday.com/releases/265307>
Serascience. (2013, August 28). "CE Mark approval for Seralite® announced, the world's first point-of-care diagnostic device for multiple myeloma." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/265307.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.